Related Experiment Videos

[Adiaspiromycosis--a little known lung disease]

Zeitschrift Fur Erkrankungen Der Atmungsorgane
|January 1, 1982
PubMed

Insights

Adiaspiromycosis, a lung disease caused by Emmonsia crescens, affects wild mammals and can spread to humans via inhaled fungal spores. Treatment often involves surgery and antifungal drugs, though modern therapies require further study.

Area of Science:

  • Mycology
  • Pulmonary Medicine
  • Veterinary Pathology

Context:

  • Adiaspiromycosis is a granulomatous pulmonary disease primarily affecting small wild mammals.
  • Humans can contract the disease through inhalation of Emmonsia crescens spores from soil.
  • Wild mammals serve as reservoirs, potentially spreading the fungus to human environments.

Purpose:

  • To describe the epidemiology, pathogenesis, and clinical aspects of adiaspiromycosis.
  • To review current diagnostic and treatment modalities for human adiaspiromycosis.
  • To highlight the role of wild mammals in the transmission cycle of Emmonsia crescens.

Summary:

  • Infection occurs via inhalation of aleuriospores, which transform into parasitic adiaspores in the lungs, reaching up to 700 microns.
  • Disease outcomes range from asymptomatic to disseminated pulmonary processes, with pathogenesis potentially involving fungal burden and reduced lung function.
  • Extrapulmonary forms are possible, and while antibody response and delayed hypersensitivity occur, cell-mediated immunity is unstudied.

Impact:

  • Current treatments include surgery and fungistatic drugs like pimaricin or amphotericin B, with corticosteroids used in select cases.
  • The efficacy of newer antifungal agents remains to be established.
  • Further research is needed into cell-mediated immunity and advanced treatment options for adiaspiromycosis.

Related Concept Videos